Related Experiment Videos
Switching between biological agents.
1Department of Rheumatology D1-2, Karolinska University Hospital and Karolinska Institute, 17176 Stockholm, Sweden. ronald.vanvollenhoven@kus.se
Clinical and Experimental Rheumatology
|November 24, 2004
Summary
Patients failing one TNF-alpha antagonist may benefit from switching to another. Switching biologic agents for rheumatic diseases can be effective, offering a viable treatment option.
Area of Science:
- Rheumatology
- Immunology
- Pharmacology
Background:
- Tumor Necrosis Factor-alpha (TNF-alpha) antagonists like infliximab, etanercept, and adalimumab demonstrate comparable efficacies in treating rheumatic diseases.
- Efficacy is primarily attributed to the neutralization of free TNF-alpha.
Purpose of the Study:
- To evaluate the clinical question of whether switching to a different TNF-alpha antagonist is a worthwhile strategy for patients who have not responded to an initial agent.
- To review existing literature and present data on the effectiveness of sequential TNF-alpha antagonist therapy.
Main Methods:
- Review of published studies addressing treatment failures with TNF-alpha antagonists.
- Detailed analysis of data from the Stockholm TNF-alpha follow-up registry (STURE).
Main Results:
- Overall findings suggest that switching between biologic agents targeting TNF-alpha can be effective for patients with rheumatic diseases.
- Specific data from the STURE registry supports the efficacy of such therapeutic switches.
Conclusions:
- Switching TNF-alpha antagonists can be an effective treatment strategy in rheumatic diseases.
- Further investigation into specific clinical scenarios and comparative methodologies for sequential therapies is warranted.